HC Wainwright Lowers Genelux (NASDAQ:GNLX) Price Target to $32.00

Genelux (NASDAQ:GNLX - Free Report) had its price target cut by HC Wainwright from $35.00 to $32.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

Genelux Stock Performance

NASDAQ GNLX traded up $0.01 during trading hours on Tuesday, hitting $5.25. 105,728 shares of the company's stock traded hands, compared to its average volume of 118,550. Genelux has a 52 week low of $4.89 and a 52 week high of $40.98. The business's fifty day moving average price is $7.74 and its two-hundred day moving average price is $13.38.

Hedge Funds Weigh In On Genelux

A number of hedge funds have recently modified their holdings of GNLX. Amalgamated Bank boosted its position in shares of Genelux by 250.8% in the third quarter. Amalgamated Bank now owns 1,077 shares of the company's stock worth $26,000 after purchasing an additional 770 shares during the period. California State Teachers Retirement System bought a new position in shares of Genelux in the second quarter worth approximately $30,000. Tower Research Capital LLC TRC bought a new position in shares of Genelux in the first quarter worth approximately $32,000. Legal & General Group Plc boosted its position in shares of Genelux by 535.2% in the third quarter. Legal & General Group Plc now owns 1,696 shares of the company's stock worth $41,000 after purchasing an additional 1,429 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Genelux by 2,105.0% in the second quarter. JPMorgan Chase & Co. now owns 2,205 shares of the company's stock worth $72,000 after purchasing an additional 2,105 shares during the period. 37.33% of the stock is currently owned by institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.